DNA vaccine trial aims to train body to fight hepatitis c
NCT ID NCT02772003
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 36 times
Summary
This early-stage trial tests a DNA vaccine for people with long-term hepatitis C infection. The vaccine is designed to help the immune system recognize and attack the virus, potentially lowering the risk of liver cancer. About 33 adults with chronic hepatitis C will receive the vaccine to check for side effects and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
Conditions
Explore the condition pages connected to this study.